Clinical Trials Directory

Trials / Completed

CompletedNCT03328247

Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma

Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma: A Randomized Patient-focused Trial of Delivering the ASICA Intervention as a Means to Earlier Detection of Recurrent and Second Primary Melanoma

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
240 (actual)
Sponsor
University of Aberdeen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The ASICA study is looking at how the UK National Health Service (NHS) might use technology in the future to more effectively support people who have been treated for melanoma.

Detailed description

All patients who have been treated for melanoma are advised to regularly examine their own skin (total-skin-self-examinations; TSSE) but research has found that many people are not shown how to do this effectively. We are investigating whether a digital app we have developed (ASICA) can help people with melanoma to use a hand-held tablet computer to do more regular and effective TSSE, and whether this would lead to earlier detection of recurrent and new primary melanomas. The ASICA app also uses the internet to enable people to electronically communicate the findings of their TSSE to a specialist nurse. All those who consent to take part in the study will be randomly allocated into one of two groups. One group will use the ASICA app in addition to their normal follow-up, the other group will continue to attend their routine melanoma follow-up only. Participants will be recruited from two UK sites - NHS Grampian and Cambridge University Hospitals.

Conditions

Interventions

TypeNameDescription
OTHERASICA digital appParticipants in the intervention arm will be trained to use ASICA (in addition to completing routine follow-up) and participants within the control arm will continue to attend their usual structured melanoma follow-up only. The hypothesis is that the ASICA intervention will increase TSSE practice in those affected by melanoma without affecting psychological well-being and lead to earlier detection of recurrent and new primary melanoma.

Timeline

Start date
2018-01-12
Primary completion
2020-03-31
Completion
2020-03-31
First posted
2017-11-01
Last updated
2021-04-28

Locations

2 sites across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT03328247. Inclusion in this directory is not an endorsement.